EGFR and neoplasm: Conversely, the higher rate of co-occurrent alterations, either “passengers” or even “drivers”, in MET, KRAS, BRAF and EGFR-driven tumors, suggests a branched clonal evolutionary process existing from the early steps of tumor progression.